Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery: An Update Meta-Analysis and...

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Pharmacology

Background:

• Conflicting evidence exists regarding levosimendan's mortality benefit in low cardiac output syndrome post-cardiac surgery.
• Previous studies yielded varied results on levosimendan's efficacy in this patient population.

Purpose of the Study:

• To evaluate the effect of levosimendan on postoperative mortality in cardiac surgery patients with impaired left ventricular function (ejection fraction ≤ 40%).

Main Methods:

• A meta-analysis of 15 randomized clinical trials involving 2,152 patients was conducted.
• Inclusion criteria focused on cardiac surgery patients with ejection fraction ≤ 40%, comparing levosimendan to placebo or other treatments.
• Trial sequential analysis (TSA) was employed to assess the reliability of the primary endpoint (postoperative mortality).

Main Results:

• Pooled analysis indicated a reduction in postoperative mortality with levosimendan (RR = 0.53).
• TSA suggested the mortality benefit finding might be a false positive, necessitating caution.
• Significant improvements were observed in cardiac index, pulmonary capillary wedge pressure, and reduced ICU stay and renal replacement therapy needs.

Conclusions:

• Levosimendan appears to decrease mortality and other adverse outcomes in cardiac surgery patients with low ejection fraction.
• However, the current evidence remains inconclusive, and further large-volume randomized clinical trials are required for definitive conclusions.